Concepedia

Kumar B. Pabbisetty

KB

6

Publications

246

Citations

6

H-Index

2005

Active since

Affiliations

Bristol-Myers Squibb (United States)(Current)

Rutgers, The State University of New Jersey

Kumar B. Pabbisetty is an author at Bristol-Myers Squibb (United States) specializing in drug discovery, medicinal chemistry, and pharmacotherapy.

ORCID

Top concepts

Publications per year

2005–2021

6

Publications

6

Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy

Andrew K. Dilger, Kumar B. Pabbisetty, James R. Corte et al. · Journal of Medicinal Chemistry · 2021 · 93 citations · Full text

Kinetic analysis of the binding of monomeric and dimeric ephrins to Eph receptors: Correlation to function in a growth cone collapse assay

Kumar B. Pabbisetty, Xin Yue, Chen Li et al. · Protein Science · 2007 · 44 citations · Full text

Chemoselective deprotection of N-Boc group in amino acids and peptides by bismuth(III) trichloride

Raghavendra S. Navath, Kumar B. Pabbisetty, Longqin Hu · Tetrahedron Letters · 2005 · 34 citations

, , +10

Novel phenylalanine derived diamides as Factor XIa inhibitors

Leon M. Smith, Michael J. Orwat, Zilun Hu et al. · Bioorganic & Medicinal Chemistry Letters · 2015 · 28 citations · Full text

, , +6

Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1<i>H</i>)-one as the P2′ Moiety

Zilun Hu, Pancras C. Wong, Paul J. Gilligan et al. · ACS Medicinal Chemistry Letters · 2015 · 26 citations · Full text

, , +15

Rows per page

1–5 of 6